Terumo (OTCMKTS:TRUMY) Sees Large Volume Increase - Still a Buy?

Key Points

• Terumo’s trading volume surged 262% to approximately 881,418 shares, while the stock rose 1.2% to $15.3630.
• Analysts at Nomura and Zacks Research upgraded Terumo to “strong buy”; MarketBeat reports an average rating of Strong Buy from two analysts.
• The company exceeded quarterly expectations, reporting $0.30 EPS versus $0.17 expected and revenue of $1.97 billion versus $1.84 billion estimated.

Terumo Corp. (OTCMKTS:TRUMY - Get Free Report) saw unusually-high trading volume on Monday. Approximately 881,418 shares were traded during mid-day trading, an increase of 262% from the previous session's volume of 243,282 shares. The stock last traded at $15.3630 and had previously closed at $15.19.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Nomura upgraded shares of Terumo from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 30th. Zacks Research raised shares of Terumo from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, October 13th. Two research analysts have rated the stock with a Strong Buy rating. According to MarketBeat.com, the stock currently has an average rating of "Strong Buy".

Terumo Stock Up 1.2%

The firm has a 50-day simple moving average of $14.96 and a two-hundred day simple moving average of $14.30. The company has a current ratio of 2.19, a quick ratio of 1.37 and a debt-to-equity ratio of 0.13. The stock has a market cap of $22.67 billion, a P/E ratio of 21.65 and a beta of 0.77.

Terumo (OTCMKTS:TRUMY - Get Free Report) last issued its earnings results on Friday, August 7th. The company reported $0.30 earnings per share for the quarter, topping analysts' consensus estimates of $0.17 by $0.13. The firm had revenue of $1.97 billion during the quarter, compared to analyst estimates of $1.84 billion. Terumo had a net margin of 13.83% and a return on equity of 10.44%. Equities research analysts expect that Terumo Corp. will post 0.86 earnings per share for the current fiscal year.

About Terumo

Terumo Corporation is a Japan-based medical technology company that develops, manufactures and sells medical devices and healthcare products. Its offerings support hospitals, physicians and other healthcare providers across areas including cardiovascular care, interventional procedures, blood management, cell and gene therapies, and general medical care.

The company's products include catheters, guidewires, stents and other devices used in cardiovascular and endovascular procedures, as well as blood bags, apheresis systems, cell-processing technologies, infusion and injection products, and hospital equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.